

Effects of high-intensity training on the quality of life of cancer patients and survivors: a systematic review with meta-analysis

LAVÍN-PÉREZ, Ana Myriam, COLLADO-MATEO, Daniel, MAYO, Xián, LIGUORI, Gary, HUMPHREYS, Liam, COPELAND, Robert James and JIMENEZ GUTIERREZ, Alfonso

Available from Sheffield Hallam University Research Archive (SHURA) at:

<https://shura.shu.ac.uk/28863/>

This document is the Supplemental Material

Citation:

LAVÍN-PÉREZ, Ana Myriam, COLLADO-MATEO, Daniel, MAYO, Xián, LIGUORI, Gary, HUMPHREYS, Liam, COPELAND, Robert James and JIMENEZ GUTIERREZ, Alfonso (2021). Effects of high-intensity training on the quality of life of cancer patients and survivors: a systematic review with meta-analysis. *Scientific Reports*, 11 (1). [Article]

Copyright and re-use policy

See <http://shura.shu.ac.uk/information.html>

Effects of high-intensity training on the quality of life of cancer patients and survivors: a systematic review with meta-analysis

Lavín-Pérez, Ana Myriam; Collado-Mateo, Daniel; Mayo, Xian; Liguori, Gary; Humphreys, Liam; Copeland, Robert James; Jiménez, Alfonso

SUPPLEMENTARY TABLE S1. Additional characteristics from the meta-analysis participants.

Study	Group	Stage (%)	Physical activity level	Study	Group	Stage (%)	Physical activity level
Egegaard et al. (2019)	CG	IIIa (28.6%) IIIb (57.1%) IV (14.3%)	NR	Martin et al. (2015) c)	CG	I (3.5%) II (54.28%) III (34.28%)	Total Activity 51.1% Moderate 4.7% Vigorous 2.6%
	HIEG	IIIa (37.5%) IIIb (50.0%) IV (12.5%)	NR		HIEG	I (11.1%) II (62.96%) III (25.92%)	Total Activity 32.5.8% Moderate 1.9% Vigorous 0.8%
Mijwel et al. (2018)	CG	I-IIa	MVPA: 8.5 % of wear time SED: 66.6 % of wear time	Martin et al. (2015) a)	LIEG	I (20%) II (68%) III (12%)	Total Activity 30% Moderate 2.7% Vigorous 1.4%
	HIEG-R		MVPA: 9.6 % of wear time SED: 63.7 % of wear time		CG	I (42%) II (50%) III (8%)	Total Activity 35.3% Moderate 3.1% Vigorous 1.6%
	HIEG-A		MVPA: 8.3 ± 2.8 % of wear time SED: 65.6 ± 6.2 % of wear time		HIEG	I (46%) II (54%)	Total Activity 20% Moderate 1.5% Vigorous 0.8 %
Adams et al. (2018)	CG	NR	Aerobic 25% Resistance 35.7%	Van Waart et al. (2015)	LIEG	I (42%) II (50%) III (8%)	Total Activity 32.2% Moderate 3.4% Vigorous 0.8%
	HIEG	NR	Aerobic 45.7% Resistance 20%		CG	I (6%) II (48%) III (46%)	Not following a formal exercise program (sedentary and active)
Van Waart et al. (2017)	CG	II (13%) III (75%) IV (13%)	Not following a formal exercise program (sedentary and active)	HIEG	I (7%) II (42%) III (51%)	CG NR <150 min moderate activity/week (42.85%) >150 min/week (57.14%) <2×20 min strenuous activity / week (100%)	
	HIEG	II (14%) III (86%) IV (0%)		LIEG-H	I (3%) II (52%) III (45%)		
	LIEG-H	II (13%) III (75%) IV (13%)		CG	NR		
Persoon et al. (2017)	CG	NR	Sports history (66%)	Møller et al. (2015)	HIEG	NR	<150 min moderate activity/week (42.85%) >150 min/week (57.14%) <2×20 min strenuous activity / week (100%)
	HIEG	NR	Sports history (61%)		LIEG	NR	<150 min moderate activity/week (26.66%) >150 min/week (78.57%) <2×20 min strenuous activity / week (100%)
Mijwel et al. (2017)	CG	I-IIa	MVPA: 68 min/day SED: 548 min/day	Edvardsen et al. (2015)	CG	I (48%) II (39%) III (7%) V (3%)	NR
	HIEG-R		MVPA: 79. min/day SED:530min/day		HIEG	I (60%) II (23%) III (17%)	NR
	HIEG-A		MVPA: 71 min/day SED: 544. min/day		CG	I (31.6) II (47.3%) III (21.1%)	NR
Toohey et al. (2016)	HIEG	NR	NR	Cornie et al. (2013)	HIEG	I (9.1%) II (81.8%) III (9.1%)	NR
	MIEG	NR	NR		LIEG	I (23.8%) II (47.6%) III (28.6%)	NR
Schmitt et al. (2016)	HIEG	NR	NR	Andersen et al. (2013)	CG	NR	Sedentary (16.3%) For pleasure (25%) Regular exercise (61.5%) Intense exercise (5.8%)
	LIEG	NR	NR		HIEG	NR	Sedentary (17.3%) For pleasure (56.7%) Regular exercise (23.1%) Intense exercise (2.9%)
Dunne et al. (2016)	CG	NR	NR	Hwang et al. (2012)	CG	II A (9.1%) IV (90.9%)	NR
	HIEG	NR	NR		HIEG	II A (7.7%) II B (15.4%) IV (76.9%)	NR
Kampshoff et al. (2015)	CG	I-II (68%) II-IV (32%)	Sport history (54%) Exercise during chemotherapy (11%)	Adamsen et al. (2009)	CG	NR	Sedentary (19.8%) For pleasure (38.1%) Regular exercise (37.3%) Intense activity (4.8%)
	HIEG	I-II (75%) II-IV (25%)	Sport history (50%) Exercise during chemotherapy (23%)		HIEG	NR	Sedentary (17.4%) For pleasure (56.8%) Regular (22.7%) Intense physical activity (3.0%)
	LMIEG	I-II (60%) II-IV (40%)	Sport history (65%) Exercise during chemotherapy (22%)				

CG: (inactive) control group; HIEG: high-intensity exercise group; HIEG-R: high-intensity exercise group with resistance component; HIEG-A: high-intensity exercise group with aerobic component; MIEG: moderate intensity exercise group; LIEG: low intensity exercise group; LMIEG: low to intensity exercise group; MVPA: moderate to vigorous physical activity; NR: not reported

SUPPLEMENTARY TABLE S2. Characteristics of the participants included only in the systematic-review.

Study	Design	Group	Sample size (% of females)	Age (SD)	Cancer type (%)	Stage (%)	Treatment	Timing	BMI	Physical activity level
Pereira et al. (2020)	Randomized Control Trial	CG	n=66 (100%)	53 (7)	Breast cancer	II	Surgery (14%) Chemotherapy (60%) Radiation therapy (70%) Hormone therapy (43%)	After	30 (4.2)	Sedentary
		HIEG	n=70 (100%)	55 (5)					31 (3.9)	
		MIEG	n=80 (100%)	51 (4)					29 (5.4)	
Christensen et al. (2018)	Safety and feasibility study	CG	n= 29 (6.89%)	27.8 (5.5)	Adenocarcinoma	0 (3%) I (17%) II (62%) III (17%)	Surgery (79.31%) Chemotherapy (89.65%)	During	27.8 (5.5)	NR
		HIEG	n= 21 (14.28%)	28.4 (5.6)		0 (14%) I (33%) II (38%) III (14%)	Surgery (90.47%) Chemotherapy (95.24%)	During	28.4 (5.6)	NR
Toohey et al. (2018)	Randomized Clinical Trial	CG	n=25(100%)	57(11.5)	Breast (83%), Ovarian (8.5%), Appedix, Cervical (8.5%)	I-II (83%) II-IV (17%)	Surgery (100%) Radiation therapy (83%) Hormone therapy (75%) Chemotherapy, (66%)	After	NR	Sedentary
		HIEG	n= 25(100%)	48 (11.9)	Breast (88%), Cervical (4%), Liver (4%), Esophageal (4%)	I-II (19%) II-IV (21%)	Surgery (88%) Radiation therapy (75%) Hormone therapy (79%) Chemotherapy (82%)	After	NR	Sedentary
		LIEG	n= 25 (100%)	52 (12.4)	Breast (75%), Ovarian (5%), Appedix (5%), Malenoma (5%), Leiomyosarcoma (5%), Unknow primary (5%)	I-II (76%) II-IV (24%)	Surgery (95%) Radiation therapy (62%) Hormone therapy (71%) Chemotherapy (71%)	After	NR	Sedentary
Brunet at al. (2017)	Non-randomized controlled pilot trial	CG	n= 13 (31%)	72	Rectal cancer	≥T2/N+	Chemoradiation (100%)	Before surgery	24.9 (3.9)	NR
		HIEG	n= 22 (36%)	64	Rectal cancer	≥T2/N+	Chemoradiation (100%)	Before surgery	27.4 (5.1)	NR
Waked et al. (2016)	Randomized control trial	CG	n=23 (100%)	48.3(8.9)	Breast cancer	Local (30.4%) Loco-regional (30.4%) Metastasis (39.1%)	Surgery (56.5%) Chemotherapy (34.8%) Radiation (8.7%)	After	NR	NR
		HIEG	n=23 (100%)	49.82 (9.9)		Local (21.7%) Loco-regional (39.1%) Metastasis (39.1%)	Surgery (47.8%) Chemotherapy (39.1%) Radiation (13.0%)	After	NR	NR
Midtgaard et al. (2013)	Randomised controlled trial	CG	n =106 (83%)	46.2 (11.6)	Breast (60.2%) Bowel (5%) Ovaries (2%) Uterus (2%) Testicles (8%)	NR	Surgery (82.07%) Chemotherapy (100%) Radiation (68.86%) Homonotherapy (47.17%)	After	25.1 (3.8)	Sedentary (13%) Walking or cycling for pleasure (60.2%) Regular physical exercise at least 3 h/week (25%)
		HIEG	n= 108 (83.3%)	48.2 (10.1)	Breast (61.1%) Bowel (6%) Ovaries (6%) Uterus (5%) Testicles (3%)	NR	Surgery (77.77%) Chemotherapy (100%) Radiation (60.18%) Homonotherapy (45.37%)	After	24.6 (3.8)	Sedentary (10.2%) Walking or cycling for pleasure (63.9%) Regular physical exercise at least 3 h/week (25.9%)

CG: (inactive) control group; HIEG: high-intensity exercise group; HIEG-R: high-intensity exercise group with resistance training; HIEG-A: high-intensity exercise group with aerobic training; MIEG: moderate intensity exercise group; LIEG: low intensity exercise group; LIEG-H: low intensity exercise group at home; NR: not reported; BMI: Body Mass Index.

SUPPLEMENTARY TABLE S3. Characteristics of the exercise interventions included only in the systematic-review.

Study	Group	Duration	Sessions duration	Weekly frequency	Setting	Exercise description	Intensity progression and control	Attendance
Pereira et al. (2020)	CG							
	HIEG	36 weeks	70 min	3 times/week	NR	10 min warm-up 30 min aerobic: 30 s intervals 20 min resistance 10 min cool-down	Aerobic: intercalated intervals of 60-80 % (HRmax) and 80-90% (hrmax) Resistance: 60% RM Additional control: RPE	
	MIEG	36 weeks	70 min	3 times/week	NR	10 min warm-up 30 min aerobic 20 min resistance 10 min cool-down	Aerobic: 60-80 % (HRmax) Resistance: 60% RM Additional control: RPE	
Christensen et al. (2018)	CG	3-20 weeks						
	HIEG	3-20 weeks	75 min	2 times/week	Centre for Physical Activity Research,	10 min cycle warm-up Aerobic:4x4 min intervals with 3 min active recovery between/ Resistance: four exercises major muscle groups: 3 series of 8-12 repetitions	Intervals: high intensity Recovery: low intensity	68.7%
Toohey et al. (2018)	CG	12 weeks						Compliance: 92%
	HIEG	12 weeks	20-30 min	3 times/week	Supervised	5 min warm-up 7x30s intervals with 1min rest 5 min cool-down	Intervals \geq 85% (HRmax) From 3 intervals in the first session to 7 intervals in week 5 Additional control: Blood pressure	
	MIEG	12 weeks	30 min	3 times/week	Supervised	5 min warm-up 20 min cycle continuous Aerobic 5 min cool-down	\leq 55% predicted maximal heart rate	
Brunet et al. (2017)	HIEG	6 weeks	30 min (first 3 sessions) 40 min	3 times/week	Hospital	5 min warm-up 3 min braked cycle ergometer intervals with 2 min intervals 5 min cool-down	3 min Intervals: moderate intensity (80% of oxygen uptake at lactate threshold) 2 min intervals: vigorous intensity (50% of the difference in work rates between peak oxygen uptake and oxygen uptake at lactate threshold)	96% (5.0)
Waked et al. (2016)	CG	8 weeks						
	HIEG	8 weeks	90 min	3 times/week	National Cancer Institute	30 min warm-up: dynamic exercises 45 min resistance: 6 exercise 3 series 5-8 rep 15 min aerobic cycling	Resistance: 70-100% RM (5.5 METs) Aerobic: 70-250 W 85-95% (HRmax) (15 METs)	
Midtgaard et al. (2013)	CG	12 months						
	HIEG	12 months	90 min	3h/week 1 time/week	Supervised	Aerobic: 30s-6 min cycle ergometers intervals with a recovery ratio of 1:2 3:1 Resistance: 3 series of 8-10 repetitions	Intervals: 30 s (maximun intensity) 6 min 90-95% (HRmáx) Resistance: 70%- 90% (RM) Resistance increased when 12 repetitions could be done	66.6%

CG: (inactive) control group; HIEG: high-intensity exercise group; HIEG-R: high-intensity exercise group with resistance component; HIEG-A: high-intensity exercise group with aerobic component; MIEG: moderate intensity exercise group; W: watiots; PP: power peak; RM: repetition maximum; METs: Metabolic equivalent; RPE: rate of perceived exertion; HR: heart rate; CPET: Cardiopulmonary exercise test; NR. Not reported.

SUPPLEMENTARY TABLE S4. HRQoL outcomes not included in the meta-analysis because not having enough data to compare.

	Study	Group	Variable	Mean pre	SD pre	Mean post	SD post	p value	
EORTC QLQ- C30	Pereira et al. (2020)	CG	Global QoL	64.5	12.9	63.3	13.4	SDBG p=0.002	
		HIEG		58.6	17	125	11.8		
		MIEG		60.7	16.7	68.7	13.6		SDBG p<0.001
	Mijwel et al (2017)	HIAG	Insomnia	31.85	25.58	27.51	28.92	NSDIG	
		HIAG	Appetite loss	24.5	26.7	19.53	24.97	NSDIG	
		HIAG	Diarrhoea	13.15	22.87	17.74	26.42	NSDIG	
		CG	Financial difficulties,	20.11	31.95	18.67	32.53	NSDIG	
		HIRG		21.73	31.75	25.45	34.71	SDIG p<0.05	
		HIAG		16.54	26.85	23.19	33.54		
	Persoon et al (2017)	CG	Disease symptomsd	19.8	14.6	18.8	17.1	NSDIG ;NSDBG	
		EG		16.6	13.1	18.7	12.8	NSDIG;NSDBG	
		CG	Side effects	21.9	11.8	12.1	8.9	NSDIG;NSDBG	
		EG		21.5	9.7	10.6	8.1	NSDIG;NSDBG	
	Schmitt et al. (2016)	HIEG	Insomnia	48.8	29.4	38.5	26.9	SDIG p=0.02 NSDBG	
		MIEG		61.5	26.9	43.5	25.2	SDIG p=0.01 NSDBG	
		HIEG	Appetite loss	7.7	20	2.5	9.2	NSDIG ; NSDBG	
		MIEG		20.5	25.6	7.6	14.5	SDIG p=0.04 NSDBG	
		HIEG	Diarrhoea	5.1	12.4	5.1	12.4	NSDIG	
		MIEG		33.3	33.4	15.3	29.2	NSDBG	
		HIEG	Financial difficulties	28.2	42.7	25.6	33.8	NSDIG NSDBG	
		MIEG		38.5	35.7	40.5	38.1	NSDIG NSDBG	
	Moller et al (2015) (a)	CG	Financial difficulties	30.3	34.82	25.93	40.06	NR	
		HIEG		15.15	22.92	14.81	29.4	NR	
		LIEG		30.3	34.82	25.93	40.06	NR	
	Moller et al (2015) (b)	CG	Financial difficulties	0	0	0	0	NR	
		HIEG		41.67	50	25	31.91	NR	
		LIEG		0	0	11.11	19.25	NR	
Adamsen (2009)	CG	Financial difficulties	14.3	27.7	13	25.9	NSDBG		
	EG		11.1	21.5	10.8	19.3	NSDBG		
SF 36	Dunne (2016)	CG	Overall QoL	71	200	71	220	NSDIG	
		EG		65	230	77	180	SDIG p=0.002 SDBG p=0.028	
	Adamsen (2009)	CG	Mental component	46.9	10.2	47.3	10	SDBG p=0.004	
		HIEG		44.2	8.4	47.4	6.7		
	Adamsen (2009)	CG	Physical component	44.3	8.3	45.1	8.5	SDBG p=0.02	
		HIEG		46.5	9.7	50.5	9.4		
	Moller (2015) (a)	CG	Role emotional	70.5	19.3	66.2	20.6	NR	
		HIEG		76	21.6	75.1	20.4	NR	
		LMIEG		69.7	43.35	70.37	42.31	NR	
	Moller (2015) Prostate cancer	CG	Role emotional	66.67	33.33	16.67	23.57	NR	
		HIEG		11.11	19.25	33.33	47.14	NR	
LMIEG		0		0	22.22	19.25	NR		
FACT G	Andersen (2013)	CG	General score	78.84	13.97	81.45	13.33	NSDBG p=0.21	
		HIEG		81.14	14.51	84.41	12.88		
		CG	Physical wellbeing	19.77	5.44	20.59	5.19		
		HIEG		20.64	5.41	21.92	4.59		NSDBG p=0.13
	Toohey et al. (2016)	CG	Functional wellbeing	17.85	5.81	18.67	5.1	NSDBG p=0.26	
		HIEG		18.93	4.97	19.92	4.88		
		HIEG	General score	77.63	13.59	89.50	6.82		SDBG p<0.05
		MIEG		81.25	9.45	85.88	7.38		
		HIEG		Physical wellbeing	22.63	5.93	24.75		1.39
MIEG	21.63	3.16	23.75		2.25	NSDIG			
HIEG		18.13	5.94	22.63	3.34	SDIG p<0.05			

FACT -B	Martin et al (2015) Breast cancer	MIEG	Functional wellbeing	20.88	3.94	23.13	3.04	NSDIG
		CG	General score	83.8	13.5	91.1	11.6	SDIG p=0.044
		HIEG		83.8	13.2	90.9	9.3	
		LIEG		81.8	15.5	84	16.8	
		CG	Physical wellbeing	22.5	4.2	24.7	2.8	SDIG p=0.019
		HIEG		21.7	5.6	24.3	3	
		LIEG		21.1	4.4	22.3	4.5	
		CG	Functional wellbeing	20.9	4.4	23.8	3.7	NR
		HIEG		20.7	4.4	23	3.2	NR
		LIEG		20.8	5	21.4	4.8	NR
		CG	FACT-B	107.6	18.5	116.2	16.9	NR
		HIEG		106.8	17.2	107.6	18.5	SDIG (CG) p=0.014
	LIEG	104.1		19.2	116.9	12.8		
	Martin et al (2015) Prostate cancer	CG	General score	87.3	12.7	90.1	9.6	SDIG p=0.044
		HIEG		84.2	11.8	86	12	
		LIEG		82.5	16.4	85.7	14.5	
		CG	Physical wellbeing	23.7	4.2	24	3.3	SDIG p=0.019
		HIEG		22.9	3.6	23.9	3.9	NR
		LIEG		22.6	4.1	24.1	3.6	NR
		CG	Functional wellbeing	22.7	5.4	24.2	3.1	NR
		HIEG		21.3	4.2	21.9	4.3	NR
		LIEG		19.4	6.5	21	5.2	NR
		CG	FACT-P	122.2	17.4	126.0	14.9	NR
		HIEG		117.2	15.4	120.5	17.1	NSDIG
		LIEG		113.9	22.4	121.5	18.8	
	Egegaard (2019)	CG	Physical well-being	19.2	8.3	22.0	4.3	NSDBG
		HIEG		21.4	6.4	20.9	5.6	
		CG	Functional well-being	17.4	7.1	17.4	4.7	NSDBG
		HIEG		17.6	5.4	18.0	5.5	
		CG	Global score	80.2	16.4	83.8	12.9	NSDBG
		HIEG		79.1	12.7	81.0	12.5	
		CG	FACT- L	99.6	19.0	106.6	14.3	NSDBG
		HIEG		96.6	14.8	99.0	16.2	
Waked (2016)	CG	Global score	80.43	10.90	82.86	12.34	NSDIG	
	HIEG		78.13	12.14	112.1	11.08	SDIG p<0.001 SDBG p<0.001	

CG: (Inactive) control group; HIEG: High-intensity exercise group; HIEG-A: High-intensity exercise group with aerobic component; MIEG: moderate intensity exercise group; SDIG: Significant difference inside group; SDBG: Significant difference between groups; NSDIG: Not significant difference inside group; NSDBG: Not significant difference between groups, NR. Not reported.

SUPPLEMENTARY TABLE S5. HRQoL outcomes not included in the meta-analysis because not reporting the necessary statistic data.

EORTC-QLQ-C30	Study	Group	Outcome measure	Statistic results	p value
	Midtgaard (2013)	CG	Global quality of life	Mean before 67.16 CI: 62.65 - 71.52 Mean after: 77.44 CI: 72.74 - 81.82	SDIG p<0.001
		HIEG		Mean before 67.21 CI: 62.70 - 71.56 Mean after: 81.71 CI: 77.16 - 85.85	SDIG p<0.001 NSDBG
		CG	Physical functioning	Mean before 67.21 CI: 62.70 - 71.56 Mean after: 81.71 CI: 77.16 - 85.85	SDIG p<0.001
		HIEG		Mean before 90.97 CI: 88.54 - 93.13 Mean after: 95.94 CI: 93.97-57	SDIG p<0.001 NSDBG
		CG	Role functioning	Mean before 82.51 CI: 77.05 - 87.37 Mean after: 90.93 CI: 85.87 - 94.96	SDIG p<0.001
		HIEG		Mean before 79.82 CI: 74.10 - 84.99 Mean after: 95.35 CI: 91.24 - 98.20	SDIG p<0.01 NSDBG
		CG	Emotional functioning	Mean before 84.13 CI: 76.96 - 85.17 Mean after: 88.59 CI: 84.47 - 92.15	SDIG p<0.01
		HIEG		Mean before 81.24 CI: 80.09 - 87.79 Mean after: 77.44 CI: 86.55 - 93.91	SDIG p<0.001 NSDBG
		CG	Cognitive functioning	Mean before 85.43 CI: 80.99 - 89.38 Mean after: 90.55 CI: 78.65 - 88.58	NSDIG
HIEG		Mean before 89.14 CI: 85.17 - 92.56		SDIG p<0.05 NSDBG	


SF-36	Midtgaard 2013		Mean after: 93.29 CI: 80.99 - 89.38		
		CG	Social functioning	Mean before 86.84 CI: 82.20 - 90.88 Mean after: 94.65 CI: 90.77 - 97.51	SDIG p<0.001
		HIEG	Social functioning	Mean before 86.55 CI: 81.88 - 90.63 Mean after: 96.3 CI: 92.90 - 98.71	SDIG p<0.01 NSDBG
		CG	Fatigue	Mean before: 34.56 CI: 29.46 - 39.85 Mean after: 22.68 CI: 17.62 - 28.18	SDIG p<0.001
		HIEG	Fatigue	Mean before:38.50 CI: 33.26 - 43.87 Mean after: 21.88 CI: 16.74 - 27.49	SDIG p<0.01 NSDBG
		CG	Nausea and vomiting	Mean before 1.03 CI: 0.48 - 1.80 Mean after: 0.54 CI: 0.12 - 1.26	NSDIG
		HIEG	Nausea and vomiting	Mean before 1.06 CI: 0.49 - 1.83 Mean after: 0.19 CI: 0.00 - 0.71	SDIG p<0.05 NSDBG
		CG	Pain	Mean before 11.16 CI: 7.53 - 15.40 Mean after: 10.38 CI: 6.41 - 15.19	NSDIG
		HIEG	Pain	Mean before: 10 CI: 6.58 - 14.05 Mean after: 6.4 CI: 3.24 - 10.54	NSDIG; NSDBG
		CG	Dyspnoea	Mean before 8.51 CI: 5.61 - 11.93 Mean after: 2.01 CI: 0.57 - 4.30	SDIG p<0.001 NSDBG
		HIEG	Dyspnoea	Mean before 4.2 CI: 2.23 - 6.77 Mean after: 1.57 CI: 0.32 - 3.75	SDIG p<0.05
		CG	Diarrhoea	Mean before 4.83 CI: 2.45 - 7.97 Mean after: 2.06 CI: 0.45 - 4.81	NSDIG
		HIEG	Diarrhoea	Mean before: 3.43 CI: 1.47 - 6.17 Mean after: 0.83 CI: 0.01 - 2.89	SDIG p<0.05 NSDBG
		CG	Constipation	Mean before 2.22 CI: 0.91 - 4.09 Mean after: 0.92 CI: 0.11 - 2.51	NSDIG
		HIEG	Constipation	Mean before 2.98 CI: 1.42 - 5.09 Mean after: 0.45 CI: 0.00 - 1.73	SDIG p<0.01 NSDBG
		CG	Appetite loss	Mean before: 0.93 CI: 0.29 - 1.94 Mean after: 0.80 CI: 0.15 - 1.97	NSDIG
		HIEG	Appetite loss	Mean before: 1.75 CI: 0.80 - 3.06 Mean after: 0.03 CI: 1.33 - 0.49	SDIG p<0.001 NSDBG
		CG	Insomnia	Mean before 23.82 CI: 16.72 - 32.54 Mean after: 18.02 CI: 11.10 - 26.20	SDIG p<0.001 NSDBG
		HIEG	Insomnia	Mean before 22.07 CI: 15.36 - 29.62 Mean after: 18.65 CI: 11.39 - 27.21	NSDIG
		CG	Financial difficulties	Mean before 9.84 CI: 5.35 - 15.49 Mean after: 8.79 CI: 4.17 - 14.90	NSDIG
		HIEG	Financial difficulties	Mean before 4.55 CI: 1.67 - 8.75 Mean after: 0.98 CI: 0.00 - 3.85	SDIG p<0.05 NSDBG
		CG	Psysical functioning	Mean before: 87.86 CI: 85.10 - 90.38 Mean after: 93.71 CI: 91.37 - 95.70	SDIG p<0.01
		HIEG	Psysical functioning	Mean before 4.55 CI: 1.67 - 8.75 Mean after: 95.44 CI: 93.29 - 97.20	SDIG p<0.001 NSDBG
		CG	Role Physical	Mean before 35.16 CI: 24.87 - 46.21 Mean after: 73.80 CI: 61.72 - 84.28	SDIG p<0.01
		HIEG	Role Physical	Mean before 31.71 CI: 21.74 - 42.61 Mean after: 80.03 CI: 68.10 - 89.73	SDIG p<0.001 NSDBG
		CG	Bodily pain	Mean before: 80.43 CI: 75.05 - 85.29 Mean after: 84.35 CI: 78.67 - 89.30	NSDIG
HIEG	Bodily pain	Mean before: 83.89 CI: 78.89 - 88.34 Mean after: 89.81 CI: 84.85 - 94.01	SDIG p<0.05 NSDBG		
CG	General health perceptions	Mean before: 68.51 - 77.86 CI: 61.08 - 69.61 Mean after: 71.01 CI: 66.40 - 75.41	SDIG p<0.001		
HIEG	General health perceptions	Mean before: 69.02 CI: 64.77 - 73.11 Mean after: 73.32 CI: 68.51 - 77.86	SDIG p<0.001 NSDBG		
CG	Vitality	Mean before: 54.76 CI: 50.39 - 59.10 Mean after: 66.54 CI: 61.80 - 71.11	SDIG p<0.001		
HIEG	Vitality	Mean before: 54.23 CI: 49.83 - 58.59 Mean after: 71.81 CI: 67.00 - 76.38	SDIG p<0.001 NSDBG		
CG	Social functioning	Mean before: 61.42 CI: 58.31 - 64.50 Mean after: 69.20 CI: 65.80 - 72.49	SDIG p<0.001		
HIEG	Social functioning	Mean before: 64.97 CI: 61.89 - 67.98 Mean after: 73.4 CI: 69.98 - 76.81	SDIG p<0.001 NSDBG		
CG	Role emotional	Mean before: 64.49 CI: 53.80 - 74.49 Mean after: 69.20 CI: 65.80 - 72.49	SDIG p<0.001		
HIEG	Role emotional	Mean before: 71.46 CI: 61.16 - 80.75 Mean after: 93.1 CI: 84.98 - 98.32	SDIG p<0.001 NSDBG		
CG	Mental health	Mean before: 75.26 CI: 72.06 - 78.33	SDIG p<0.05		

FACT-G	Toohey et al. (2018)	HIEG		Mean after: 80.29 CI: 76.94 - 83.45 Mean before 74.73 CI: 71.49 - 77.84 Mean after: 82.48 CI: 79.07 - 85.65	SDIG p<0.001 NSDBG
		CG	Physical component scale	Mean before: 45.81 CI: 44.33 - 47.29 Mean after: 49.38 CI: 47.73 - 51.02	SDIG p<0.001
		HIEG		Mean before: 46.68 CI: 45.19 - 52.26 Mean after: 50.50 CI: 48.74 - 52.26	SDIG p<0.001 NSDBG
		CG	Mental component scale	Mean before 44.9873 CI: 43.13 - 46.85 Mean after: 48.70 CI: 46.60 - 50.80	SDIG p<0.01
		HIEG		Mean before: 45.3077 CI: 43.43 - 47.19 Mean after: 50.71 CI: 48.45 - 52.98	SDIG p<0.001 NSDBG
		CG	Physical wellbeing	Mean after: 21.5 Mean difference: -0.3 CI: -1.09-0.51	
	HIEG	Mean after: 25 Mean difference: 0.89 CI: 0.30-1.48		SDBG (CG) p=0.02	
	MIEG	Mean after: 22.48 Mean difference: 0.61 CI: -0.001-1.23		SDBG (CG) p=0.02	
	CG	Social wellbeing	Mean after: 22.33 Mean difference: 0.2 CI: -0.85-0.75		
	HIEG		Mean after: 22.04 Mean difference: 0.35 CI: -0.22-0.92	NSDBG (CG) p=0.057 NSDBG (MIEG) p=0.057	
	MIEG		Mean after: 22.04 Mean difference: 0.2 CI: -0.40-0.80		
	CG	Emotional wellbeing	Mean after: 17.92 Mean difference: -0.11 CI: -0.92-0.69		
	HIEG		Mean after: 19.42 Mean difference: 1.04 CI: 0.43-1.64	SDBG (CG) p<0.01 SDBG (MIEG) p<0.01	
	MIEG		Mean after: 17.57 Mean difference: 0.15 CI: -0.45-0.76		
CG	Functional wellbeing	Mean after: 19.58 Mean difference: -0.02 CI: -0.82-0.78			
HIEG		Mean after: 23.17 Mean difference: 0.96 CI: 0.37-1.56	SDBG (CG) p=0.02 SDBG (MIEG) p=0.02		
MIEG		Mean after: 21.29 Mean difference: 0.64 CI: 0.02-1.26			
CG	Overall quality of life	Mean difference: -0.15 CI: -0.95-0.65			
HIEG		Mean difference: 1.11 CI: 0.50- 1.72	SDBG (CG) p<0.01 SDBG (MIEG) p<0.01		
MIEG		Mean difference: 0.57 CI: -0.00-1.20			
CG: (inactive) control group; HIEG: high-intensity exercise group; HIEG-A: high-intensity exercise group with aerobic component; MIEG: moderate intensity exercise group; SDIG: Significant difference inside group; SDBG: Significant difference between groups; NSDIG: not significant difference inside group; NSDBG: not significant difference between groups; NR: not reported; CI: confident interval.					

High Intensity Exercise Programmes Effects in Each Health-Related Quality of Life Dimension

Global health status is presented in Figure S1. HIEG presented a higher global health status in comparison with CG ($p=0.0002$, with SMD of 0.25 and a 95% CI from 0.12 to 0.39). Differences between HIEG and LMEG were not significant ($p=0.12$). Improvements in Global health status were observed during ($p=0.02$, with SMD of 0.22 and a 95% CI from 0.03 to 0.40) and after ($p=0.003$, with SMD of 0.30 and a 95% CI from 0.10 to 0.50) cancer treatment. Regarding the type of interventions, only the following significant results could be reported: 1) only those programmes with resistance component achieved significant results ($p=0.0008$, with SMD of 0.25 and a 95% CI from 0.10 to 0.39); 2) interventions with a duration of eight weeks or less ($p=0.04$, with SMD of 0.23 and a 95% CI from 0.01 to 0.45), as well as longer ones ($p=0.002$, with SMD of 0.27 and a 95% CI from 0.10 to 0.45), are effective; 3) a frequency of 2 days/week ($p=0.002$, with a SMD of 0.26 and a 95% CI from 0.10 to 0.42) and also 3 days/week ($p=0.03$, with a SMD of 0.22 and a 95% CI from 0.02 to 0.42); 4) interventions should involve 120 minutes of exercise or more ($p=0.03$, with SMD of 0.18 and a 95% CI from 0.02, to 0.42); and, 5) the part of the session of high-intensity should be longer than 15 minutes ($p=0.001$, with a SMD of 0.32 and a 95% CI from 0.13 to 0.51), less than 15 minutes was reported as $p=0.05$.


Supplementary Figure S1. Meta-analysis results of the Global health dimension.



Functional scale


Regarding physical functioning (Figure S2), HIEG significantly improved the physical component when compared to the CG ($p=0.0009$, with SMD of 0.30 and a 95% CI from 0.12 to 0.49). Differences between HIEG and LMEG were not significant ($p=0.91$). Concerning cancer treatment timing, increases were only reached in programmes developed during treatment ($p=0.0005$, with SMD of 0.42 and a 95% CI from 0.18 to 0.66) but not after treatment ($p=0.22$). For type of exercise, programmes with any kind of resistance training increased physical functioning significantly ($p=0.0006$, with SMD of 0.34 and a 95% CI from 0.15 to 0.53). In contrast, interventions with only cardiovascular training did not improve physical function ($p=0.17$). The significant physical functioning improvements were dependent on the training duration: interventions of 8 weeks or less ($p=0.04$, with SMD of 0.04 and a 95% CI from 0.01 to 0.45), programmes with a frequency of 2 days/week ($p=0.005$, with SMD of 0.37 and a 95% CI from 0.11 to 0.62) and at least 120 minutes of exercise/week ($p=0.006$, with SMD of 0.24 and a 95% CI from 0.07 to 0.40), and work-out with a high-intensity part of the session of 15 minutes or less ($p=0.003$, with a SMD of 0.29 and a 95% CI from 0.10 to 0.48).

Supplementary Figure S2. Meta-analysis results of the Physical functioning dimension.



Considering the role functioning, or physical role, the HIEG showed significant enhancements versus CG ($p=0.001$, with SMD of 0.23 and a 95% CI from 0.09 to 0.37). Differences between HIEG and LMEG were not significant ($p=0.15$) (Figure S3). As for the CG and HIEG comparison, programmes with interventions implemented during the cancer treatment had significant benefits ($p=0.0003$, with SMD of 0.35 and a 95% CI from 0.16 to 0.54), however, programmes that were initiated after treatment did not ($p=0.37$), and only significant improvements were found in programmes of 8 weeks or less ($P=0.02$, with SMD of 0.26 and a 95% CI from 0.04 to 0.49), with a frequency of 3 times/week ($P=0.04$, with SMD of 0.21 and a 95% CI from 0.01 to 0.42) and having a high-intensity part of the session of 15 minutes or less ($p=0.0004$, with SMD of 0.34 and a 95% CI from 0.15 to 0.54).


Supplementary Figure S3. Meta-analysis results of the Role functioning/Physical role dimension.



CG: inactive control group; LMEG: low to moderate intensity exercise group; HIEG: high-intensity exercise group; * specific duration of the high-intensity exercise part (with rests)

No significant effects were noted for emotional wellbeing or mental health when comparing HIEG results with CG or with LMEG (Figure S4) as well as in the cancer treatment timing subgroup analysis. However, exercise programmes with only cardiovascular components showed positive significant differences between groups ($p=0.007$, with SMD of 0.36 and a 95% CI from 0.10 to 0.63) which did not occur when resistance training was used exclusively or when added ($p=0.14$). No statistical differences were found in the combination of programmes according to the duration characteristics analysis done.


Supplementary Figure S4. Meta-analysis results of the Emotional functioning/ Wellbeing and Mental health



CG: inactive control group; LMEG: low to moderate intensity exercise group; HIEG: high-intensity exercise group; * specific duration of the high-intensity exercise part (with rests)

Statistical improvements were found in cognitive functioning in the overall analysis of HIEG versus CG ($p=0.001$, with SMD of 0.22 and a 95% CI from -0.01 to 0.39) but not in the HIEG and LMEG comparison ($p=0.07$) (Figure S5). When considering intervention duration, statistical increases were found in programmes of more than 8 weeks ($p=0.04$, with SMD of 0.20 and a 95% CI from 0.01 to 0.40), with an exercise frequency of 2 times/week ($p=0.003$, with SMD of 0.25 and a 95% CI from 0.08 to 0.42) and both, sessions with a high-intensity part of 15 minutes or less ($p=0.04$, with SMD of 0.20 and a 95% CI of 0.10 and a 95% CI from 0.01 to 0.39) and sessions with a longer duration of this part ($p=0.02$, with SMD of 0.23 and a 95% CI from 0.04 to 0.41).


Supplementary Figure S5. Meta-analysis results of the Cognitive functioning dimension.



CG: inactive control group; LMEG: low to moderate intensity exercise group; HIEG: high-intensity exercise group; * specific duration of the high-intensity exercise part (with rests)

Regarding social functioning, there were statistically significant improvements in the HIEG compared to the inactive CG ($p=0.03$, with SMD of 0.12 and a 95% CI from 0.01 to 0.23), but not in contrast to LMEG ($p=0.62$) (Figure S6). Only those interventions carried out during the cancer treatment had significant increases ($p=0.03$, with SMD of 0.16 and a 95% CI from 0.01 to 0.32). Moreover, only the interventions involving just aerobic exercise reported significant enhancements in social functioning ($p=0.03$, with SMD of 0.29 and a 95% CI from 0.03 to 0.55). In terms of groups created based on their duration characteristics, there were no statistically significant increases in any of the analyses, except programmes with a high-intensity training component of more than 15 minutes duration ($p=0.03$, with SMD of 0.17 and a 95% CI from 0.01 to 0.33).

Supplementary Figure S6. Meta-analysis results of the Social functioning dimension.




CG: inactive control group; LMEG: low to moderate intensity exercise group; HIEG: high-intensity exercise group; * specific duration of the high-intensity exercise part (with rests)

Symptom scale


As for fatigue or vitality outcomes, statistical improvements were achieved when contrasting HIEG and CG outcomes ($p<0.0001$, with SMD of -0.32 and a 95% CI from -0.47 to -0.18) but not with the comparison to LMEG ($p=0.62$) (Figure S7). All the sub-analysis related to the exercise intervention characteristic reported a significant difference between HIEG and CG. In the sub-analysis of all the comparisons related to the intervention's type of exercise and duration, statistical differences between HIEG and CG fatigue were shown. Bodily pain, dyspnea and insomnia, reported significant improvement in the overall comparison of HIEG and CG only ($p=0.02$, with SMD of -0.18 and a 95% CI from -0.21 to -0.02 in pain analysis; $p=0.002$ with SMD of -0.34 and a 95% CI from -0.55 to -0.13 in the dyspnoea results and $p=0.003$, with SMD of -0.29 and a 95% CI from -0.47 to -0.10 in insomnia) (Figures S8 and S9). Thus, in diarrhoea, nausea, constipation and appetite loss significant increases after exercise interventions were not achieved in any of the analyses realized (Figures S9 and S10)

Supplementary Figure S7. Meta-analysis results of the Fatigue/ Vitality dimension.




CG: inactive control group; LMEG: low to moderate intensity exercise group; HIEG: high-intensity exercise group; * specific duration of the high-intensity exercise part (with rests)

Supplementary Figure S8. Meta-analysis results of the Bodily Pain dimension.



CG: inactive control group; LMEG: low to moderate intensity exercise group; HIEG: high-intensity exercise group; * specific duration of the high-intensity exercise part (with rests)


Supplementary Figure S9. Meta-analysis results of the Dyspnoea, Diarrhoea and Nausea and vomiting dimensions.




CG: inactive control group; LMEG: low to moderate intensity exercise group; HIEG: high-intensity exercise group.

Supplementary Figure S10. Meta-analysis results of the Insomnia, Constipation and Appetite loss dimensions.


Insomnia



Constipation



Appetite loss




CG: inactive control group; LMEG: low to moderate intensity exercise group; HIEG: high-intensity exercise group.


META-ANALYSIS RESULTS

Supplementary Figure S11: Effects in the global health dimension of the comparisons between high-intensity training group and control group, and high-intensity training group and low-intensity exercise group.


Global health dimension: Comparison between high-intensity group and control group




Global health dimension: Comparison between high-intensity group and low-moderate intensity group



Supplementary Figure S12: Effects of high-intensity training in global health according to the treatment timing.




Supplementary Figure S13: Effects of the type of exercise in global health dimension.




Supplementary Figure S14: Effects of the exercise programs length in global health dimension.

Global health dimension: Eight weeks of exercise program or less




Global health dimension: More than eight weeks of exercise program




Supplementary Figure S15: Effects of the weekly exercise frequency in global health dimension

Global health dimension: 2 times per week




Global health dimension: 3 times per week




Supplementary Figure S16: Effects of training minutes per week in global health dimension.

Global health dimension: Less than 120 minutes of exercise per weeks




Global health dimension: 120 minutes or more of exercise per weeks




Supplementary Figure S17: Effects of the high-intensity training part duration in global health dimension.

Global health: 15 minutes or less of high-intensity training




Global health: More than 15 minutes of high-intensity training




Supplementary Figure S18: Effects in the physical functioning dimension of the comparisons between high-intensity training group and control group, and high-intensity training group and low-intensity exercise group.


Physical functioning dimension: Comparison between high-intensity group and control group.




Physical functioning dimension: Comparison between high-intensity group and low-moderate intensity group





Supplementary Figure S19: Effects of high-intensity training in physical functioning according to the treatment timing





Physical functioning dimension: After treatment



Supplementary Figure S20: Effects of the type of exercise in physical functioning dimension.




Supplementary Figure S21: Effects of the exercise programs length physical functioning dimension.




Supplementary Figure S22: Effects of the weekly exercise frequency in physical functioning dimension

Physical functioning dimension: 2 times per week




Physical functioning dimension: 3 times per week




Supplementary Figure S23: Effects of training minutes per week in physical functioning dimension.

Physical functioning dimension: Less than 120 minutes of exercise per weeks




Physical functioning dimension: 120 minutes or more or exercise per weeks




Supplementary Figure S24: Effects of the high-intensity training part duration in physical functioning dimension

Physical functioning dimension: 15 minutes or less of high-intensity training




Physical functioning dimension: More than 15 minutes of high-intensity training




Supplementary Figure S25: Effects in the role functioning dimension of the comparisons between high-intensity training group and control group, and high-intensity training group and low-intensity exercise group.

Role functioning dimension: Comparison between high-intensity group and control group




Role functioning dimension: Comparison between high-intensity group and low-moderate intensity group




Supplementary Figure S26: Effects of high-intensity training in role functioning according to the treatment timing.

Role functioning dimension: During treatment




Role functioning dimension: After treatment




Supplementary Figure S27: Effects of the exercise programs length in role functioning dimension.

Role functioning dimension: Eight weeks of exercise program or less




Role functioning dimension: More than eight weeks of exercise program




Supplementary Figure S28: Effects of the weekly exercise frequency in role functioning dimension.

Role functioning dimension: 2 times per week




Role functioning dimension: 3 times per week




Supplementary Figure S29: Effects of training minutes per week in role functioning dimension.

Role functioning dimension: 15 minutes or less of high-intensity training




Role functioning dimension: More than 15 minutes of high-intensity training




Supplementary Figure S30: Effects of high-intensity exercise in emotional functioning according to the treatment timing.

Emotional functioning dimension: Comparison between high-intensity group and control group.




Emotional functioning dimension: Comparison between high-intensity group and low-moderate intensity group




Supplementary Figure S31: Effects of high-intensity training in global health according to the treatment timing.

Emotional functioning dimension: During treatment




Emotional functioning dimension: After treatment




Supplementary Figure S32: Effects of the type pf exercise in global health dimension.

Emotional functioning dimension: High-intensity cardiovascular training




Emotional functioning dimension: High-intensity cardiovascular training + Resistance training




Supplementary Figure S33 Effects of the exercise programs length in emotional functioning dimension.

Emotional functioning dimension: Eight weeks of exercise program or less




Emotional functioning dimension: More than eight weeks of exercise program




Supplementary Figure S34: Effects of the weekly exercise frequency in emotional functioning dimension.

Emotional functioning dimension: 2 times per week




Emotional functioning dimension: 3 times per week




Supplementary Figure S35: Effects of training minutes per week in emotional functioning dimension.

Emotional functioning dimension: Less than 120 minutes of exercise per week




Emotional functioning dimension: 120 minutes or more of exercise per week




Supplementary Figure S36: Effects of the high-intensity training part duration in emotional functioning dimension.

Emotional functioning dimension: 15 minutes or less of high-intensity training




Emotional functioning dimension: More than 15 minutes of high-intensity training




Supplementary Figure S37: Effects in the cognitive functioning dimension of the comparisons between high-intensity training group and control group, and high-intensity training group and low-intensity exercise group.

Cognitive functioning dimension: Comparison between high-intensity group and control group




Cognitive functioning dimension: Comparison between high-intensity group and low-moderate intensity




Supplementary Figure S38: Effects of the exercise programs length in global health dimension.

Cognitive functioning dimension: Eight weeks of exercise program or less




Cognitive functioning dimension: More than eight weeks of exercise program




Supplementary Figure S39: Effects of the weekly exercise frequency in cognitive functioning dimension.

Cognitive functioning dimension: 2 times per week




Cognitive functioning dimension: 3 times per week




Supplementary Figure S40: Effects of the high-intensity training part duration in cognitive functioning dimension.

Cognitive functioning dimension: 15 minutes or less of high-intensity training




Cognitive functioning dimension: More than 15 minutes of high-intensity training




Supplementary Figure S41: Effects in social functioning dimension of the comparisons between high-intensity training group and control group, and high- intensity training group and low- intensity exercise group.

Social functioning dimension: Comparison between high-intensity group and control group



Social functioning dimension: Comparison between high-intensity group and low-moderate intensity group




Supplementary Figure S42: Effects of high-intensity training in social functioning according to the treatment timing.

Social functioning dimension: During treatment

Study or Subgroup	High-Intensity group			Control group			Weight	Std. Mean Difference IV, Random, 95% CI
	Mean	SD	Total	Mean	SD	Total		
Adamsen 2009	45	5.1	35	42.6	7.4	27	8.9%	0.38 [-0.12, 0.89]
Andersen 2013	82.6	20.5	135	79.4	20.8	134	40.0%	0.15 [-0.08, 0.39]
Egegaard 2019	23.3	5.8	8	24.2	3.8	5	1.8%	-0.16 [-1.28, 0.96]
Hwang 2012	91	12.9	13	87.8	21.8	11	3.5%	0.18 [-0.63, 0.98]
Mijwel 2017	62.32	46.87	74	63.3	27.67	60	19.8%	-0.02 [-0.37, 0.32]
Moller 2015 (a)	87.04	16.2	9	74.07	14.7	9	2.4%	0.80 [-0.17, 1.77]
Moller 2015 (b)	75	31.91	4	66.67	47.14	2	0.8%	0.18 [-1.52, 1.89]
Van Wart 2015	73.5	21.6	76	67.9	29.1	77	22.7%	0.22 [-0.10, 0.54]
Total (95% CI)			354			325	100.0%	0.16 [0.01, 0.32]

Heterogeneity: Tau² = 0.00; Chi² = 3.98, df = 7 (P = 0.78); I² = 0%

Test for overall effect: Z = 2.13 (P = 0.03)




Social functioning dimension: After treatment

Study or Subgroup	High-intensity group			Control group			Weight	Std. Mean Difference IV, Random, 95% CI
	Mean	SD	Total	Mean	SD	Total		
Adams 2018	45	5.1	35	42.6	7.4	27	13.0%	0.38 [-0.12, 0.89]
Comie 2013	48.2	8.4	22	48.5	12.1	19	8.9%	-0.03 [-0.64, 0.59]
Kampshoff 2015	89.6	15.1	91	85.2	21.7	91	39.3%	0.23 [-0.06, 0.53]
Martin 2015 (a)	24	3.5	12	22.1	5.4	23	6.7%	0.38 [-0.32, 1.09]
Martin 2015 (c)	20.2	3.6	26	21.5	4.4	25	10.9%	-0.32 [-0.87, 0.23]
Persoon 2017	86	20.3	50	83.7	20.4	47	21.1%	0.11 [-0.29, 0.51]
Total (95% CI)			236			232	100.0%	0.15 [-0.03, 0.34]

Heterogeneity: Tau² = 0.00; Chi² = 4.67, df = 5 (P = 0.46); I² = 0%

Test for overall effect: Z = 1.65 (P = 0.10)




Supplementary Figure S43: Effects of the type of exercise in social functioning dimension.

Social functioning dimension: High-intensity cardiovascular training

Study or Subgroup	High-Intensity group			Control group			Weight	Std. Mean Difference IV, Random, 95% CI
	Mean	SD	Total	Mean	SD	Total		
Adams 2018	45	5.1	35	42.6	7.4	27	26.8%	0.38 [-0.12, 0.89]
Egegaard 2019	23.3	5.8	8	24.2	3.8	5	5.5%	-0.16 [-1.28, 0.96]
Hwang 2012	91	12.9	13	87.8	21.8	11	10.6%	0.18 [-0.63, 0.98]
Mijwel 2017	71.33	23.94	70	63.3	27.67	60	57.1%	0.31 [-0.04, 0.66]
Total (95% CI)			126			103	100.0%	0.29 [0.03, 0.55]

Heterogeneity: Tau² = 0.00; Chi² = 0.84, df = 3 (P = 0.84); I² = 0%

Test for overall effect: Z = 2.16 (P = 0.03)




Social functioning dimension: High-intensity cardiovascular training + Resistance training

Study or Subgroup	High-Intensity group			Control group			Weight	Std. Mean Difference IV, Random, 95% CI
	Mean	SD	Total	Mean	SD	Total		
Adamsen 2009	82.6	20.5	135	79.4	20.8	134	22.6%	0.15 [-0.08, 0.39]
Andersen 2013	23.25	3.84	106	23.27	3.73	107	17.9%	-0.01 [-0.27, 0.26]
Comie 2013	48.2	8.4	22	48.5	12.1	19	3.4%	-0.03 [-0.64, 0.59]
Kampshoff 2015	89.6	15.1	91	85.2	21.7	91	15.2%	0.23 [-0.06, 0.53]
Martin 2015 (a)	24	3.5	12	22.1	5.4	23	2.6%	0.38 [-0.32, 1.09]
Martin 2015 (c)	20.2	3.6	26	21.5	4.4	25	4.2%	-0.32 [-0.87, 0.23]
Mijwel 2017	62.32	46.87	74	63.3	27.67	60	11.2%	-0.02 [-0.37, 0.32]
Moller 2015 (a)	87.04	16.2	9	74.07	14.7	9	1.4%	0.80 [-0.17, 1.77]
Moller 2015 (b)	75	31.91	4	66.67	47.14	2	0.4%	0.18 [-1.52, 1.89]
Persoon 2017	86	20.3	50	83.7	20.4	47	8.2%	0.11 [-0.29, 0.51]
Van Wart 2015	73.5	21.6	76	67.9	29.1	77	12.8%	0.22 [-0.10, 0.54]
Total (95% CI)			605			594	100.0%	0.11 [-0.00, 0.22]


Heterogeneity: Tau² = 0.00; Chi² = 7.61, df = 10 (P = 0.67); I² = 0%

Test for overall effect: Z = 1.91 (P = 0.06)




Supplementary Figure S44: Effects of the exercise programs length in social functioning dimension.

Social functioning dimension: Eight weeks of exercise program or less




Social functioning dimension: More than eight weeks of exercise program




Supplementary Figure S45: Effects of the weekly exercise frequency in social functioning dimension

Social functioning dimension: 2 times per week




Social functioning dimension: 3 times per week




Supplementary Figure S46: Effects of training minutes per week in social functioning dimension.

Social functioning dimension: Less than 120 minutes of exercise per weeks




Social functioning dimension: 120 minutes or more of exercise per weeks




Supplementary Figure S47 Effects of the high-intensity training part duration in social functioning dimension.

Social functioning dimension: 15 minutes or less of high-intensity training




Social functioning dimension: More than 15 minutes of high-intensity training




Supplementary Figure S48: Effects in the fatigue dimension of the comparisons between high-intensity training group and control group, and high- intensity training group and low- intensity exercise group.

Fatigue dimension: Comparison between high-intensity group and control group




Fatigue dimension: Comparison between high-intensity group and low-moderate intensity group




Supplementary Figure S49: Effects of high-intensity training in fatigue according to the treatment timing.

Fatigue functioning dimension: During treatment




Fatigue functioning dimension: After treatment




Supplementary Figure S50: Effects of the weekly exercise frequency in fatigue dimension.

Fatigue functioning dimension: 2 times per week




Fatigue functioning dimension: 3 times per week




Supplementary Figure S51: Effects of training minutes per week in fatigue dimension

Fatigue dimension: Less than 120 minutes of exercise per week




Fatigue dimension: 120 minutes or more of exercise per week




Supplementary Figure S52: Effects of the high-intensity training part duration in fatigue dimension

Fatigue dimension: 15 minutes or less of high-intensity training




Fatigue dimension: More than 15 minutes of high-intensity training




Supplementary Figure S53: Effects in the bodily pain dimension of the comparisons between high-intensity training group and control group, and high- intensity training group and low- intensity exercise group.

Bodily pain dimension: Comparison between high-intensity group and control group




Bodily pain dimension: Comparison between high-intensity group and low-moderate intensity group




Supplementary Figure S54: Effects of the exercise programs length in bodily pain dimension

Bodily pain dimension: Eight weeks of exercise program or less




Bodily pain dimension: More than eight weeks of exercise program




Supplementary Figure S55: Effects of the weekly exercise frequency in bodily pain dimension.

Bodily pain dimension: 2 times per week




Bodily pain dimension: 3 times per week




Supplementary Figure S56: Effects of the high-intensity training part duration in bodily pain dimension.

Bodily pain dimension: 15 minutes or less of high-intensity training




Bodily pain dimension: More than 15 minutes of high-intensity training




Supplementary Figure S57: Effects in the dysnoea dimension of the comparisons between high-intensity training group and control group, and high- intensity training group and low- intensity exercise group.

Dyspnoea dimension: Comparison between high-intensity group and control group




Dyspnoea dimension: Comparison between high-intensity group and low-moderate intensity group




Supplementary Figure S58: Effects in the diarrhoea dimension of the comparisons between high-intensity training group and control group, and high- intensity training group and low- intensity exercise group.

Diarrhoea dimension: Comparison between high-intensity group and control group




Diarrhoea dimension: Comparison between high-intensity group and low-moderate intensity group




Supplementary Figure S59: Effects in the nausea dimension of the comparisons between high-intensity training group and control group.

Nausea dimension: Comparison between high-intensity group and control group.




Supplementary Figure S60: Effects in the constipation dimension of the comparisons between high-intensity training group and control group.

Constipation dimension: Comparison between high-intensity group and control group.




Supplementary Figure S61: Effects in the insomnia dimension of the comparisons between high-intensity training group and control group, and high- intensity training group and low- intensity exercise group.

Insomnia dimension: Comparison between high-intensity group and control group




Insomnia dimension: Comparison between high-intensity group and low-moderate intensity group



Supplementary Figure S62: Effects in the appetite loss dimension of the comparisons between high-intensity training group and control group, and high- intensity training group and low- intensity exercise group.

Appetite loss dimension: Comparison between high-intensity group and control group



Appetite loss dimension: Comparison between high-intensity group and low-moderate intensity group

